Nacev, Benjamin A.
Jones, Kevin B.
Intlekofer, Andrew M. http://orcid.org/0000-0001-9046-6549
Yu, Jamie S. E.
Allis, C. David http://orcid.org/0000-0001-7589-713X
Tap, William D.
Ladanyi, Marc
Nielsen, Torsten O. http://orcid.org/0000-0003-3769-2517
Article History
Accepted: 26 June 2020
First Online: 11 August 2020
Competing interests
: A.M.I. previously consulted for Foundation Medicine, Inc. W.D.T. reports personal fees from Agios Pharmaceuticals, Eli Lilly, EMD Serono, Eisai, Janssen, Immune Design, Daiichi Sankyo, Blueprint, Loxo, GlaxoSmithKline, NanoCarrier and Deciphera outside the submitted work. In addition, W.D.T. has a patent Companion Diagnostic for CDK4 inhibitors (14/854,329 pending to Memorial Sloan Kettering Cancer Center (MSKCC)/Sloan Kettering Institute (SKI). W.D.T. is also on the scientific Advisory Board of Certis Oncology Solutions and Atropos Therapeutics (both stock ownership) and is a consultant for Daiichi Sankyo (FDA Oncologic Drugs Advisory Committee (ODAC) meeting, pexidartinib). T.O.N. has a patent on the Prosigna breast cancer diagnostic (Veracyte Technologies) outside the submitted work. B.A.N., K.B.J., J.S.E.Y., C.D.A. and M.L. declare no competing interests.